Benralizumab in severe eosinophilic asthma by biologic use and key clinical subgroups: real-world XALOC-1 programme: a plain language summary of publication
Bibliographic record
Abstract
Plain Language SummaryWhat is this summary about?This is a summary of an article originally published in the European Respiratory Journal, which presented combined results from five retrospective real-world studies (i.e., studies looking at data collected during historical medical appointments) that each took place in a different country and which, together, formed the XALOC-1 study programme. XALOC-1 looked at how effective benralizumab injections were in real-world clinical practice at treating a type of asthma called ‘severe eosinophilic asthma’.What were the main results of the XALOC-1 study programme?Patients with severe eosinophilic asthma treated with benralizumab in the real world had a reduction in the number of asthma attacks, a reduction in their dose of steroid tablets (sometimes to zero), and improved lung function and asthma symptom control. This was true regardless of whether patients had or had not responded well to other biologic therapies before starting benralizumab. Patients who had nasal polyps or signs of allergy-related asthma also benefitted from treatment with benralizumab.What do the results of XALOC-1 mean?In real-world clinical practice (during medical appointments, rather than a specially designed clinical study), patients with severe eosinophilic asthma treated with benralizumab have reduced symptom severity and improved quality of life.Clinical trial number: XALOC-1 clinical trial https://pmc.ncbi.nlm.nih.gov/articles/PMC11237372/
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.026 | 0.073 |
| Meta-epidemiology (narrow) | 0.001 | 0.001 |
| Meta-epidemiology (broad) | 0.003 | 0.005 |
| Bibliometrics | 0.002 | 0.005 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.005 | 0.002 |
| Open science | 0.001 | 0.002 |
| Research integrity | 0.003 | 0.003 |
| Insufficient payload (model declined to judge) | 0.015 | 0.003 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".